MarketsandMarkets: Dental Devices and Consumables Market to be Worth US$26 Billion by 2014WILMINGTON, Delaware - The dental devices report forecasts the size of global dental equipment and consumables market over the period 2009 - 2014. The report analyses the key trends of the market, and segments the global dental equipment and consumables market by components and into various geographic regions (with the market size of each of these regions). Further, it discusses the key market drivers, restraints and opportunities of the global dental equipment and consumables market. MarketsandMarkets: Global Biomarker Market Worth US$ 20.5 Billion by 2014WILMINGTON, Delaware - The Global Biomarker Market report analyzes the biomarker tools and services market over the period 2009-2014. The report studies the major market drivers, restraints, and opportunities for the global biomarker market; and also evaluates the major trends in the macro- and micro-markets with respect to different geographic regions. World’s Largest Medical Tourism and Global Healthcare Conference, October 26-28th, Announces Record Attendance, Distinguished Speakers and SponsorsLOS ANGELES - The 2nd Annual World Medical Tourism & Global Health Congress, the largest medical tourism congress in the world, announces speakers, sponsors and record increase in attendance this coming October 26-28th 2009 in Los Angeles, California. www.medicaltourismcongress.com/ Over 60 countries confirmed participation. Up to 5,000 private one-on-one networking sessions will be arranged through special networking software, allowing each delegate to schedule up to 80 meetings during the 3-day conference. Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & DevelopmentCOPENHAGEN and OSLO - - Experienced Biopharmaceutical Executives Form new Leadership Team at Antibody Medicines Company Pitavastatin is Non-Inferior to Atorvastatin and Simvastatin and Demonstrates Sustained Efficacy and Tolerability Over 52 WeeksBARCELONA, Spain - - Pitavastatin Represents Long-Term Treatment Option for Patients With Primary Hypercholesterolaemia or Combined Dyslipidaemia New Insights Link Low HDL-Cholesterol and Elevated Triglycerides With Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-CholesterolBARCELONA - - Surveys Establish Residual Vascular Risk is Associated With Atherogenic Dyslipidemia Suggesting the Need to Reconsider Approach to Management of Lipids Edoxaban - Next Generation Oral Anticoagulant Under Investigation to Help Prevent Stroke in Patients With Atrial FibrillationBARCELONA, Spain - - New Treatment Could Offer Further Option in Addition to Current Standard of Care in Thromboembolic Disease EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 AuctionWELLESLEY HILLS, Massachusetts - Joseph F. Finn, Jr., C.P.A. (”Finn”), announced today that the P2Y2 Gastrointestinal Early Development Candidate Program will be part of the intellectual property offered for sale at the September 30, 2009 auction. Blood Test May Predict Course of MSLONDON - Scientists have discovered a blood test that could predict the course of multiple sclerosis (MS), or even indicate who is likely to develop the condition after a first MS-like attack. Prescient Medical Inc. Featured on FOX Business NetworkDOYLESTOWN, Pennsylvania - Prescient Medical Inc. announced that CEO Patricia Scheller, appeared on FOX Business Network (FBN) to discuss the company’s groundbreaking products and recent achievement of CE Mark approval for their vProtect(TM) Luminal Shield Stent System. Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International MarketsBARCELONA, Spain - - New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes Nuevolution Announces New Research Collaboration With Big PharmaCOPENHAGEN - - Partnership to use Nuevolution’s Chemetics(R) Technology for Lead Discovery 80 Million European Runners Reveal Their Reasons to RunHOOFDDORP, The Netherlands - - ASICS Looks Into the Runner’s Mind The world of running is experiencing a ’second running wave’, with approximately 36% of 15 to 65 year-old Europeans taking to the streets, parks, forests, and gyms. But how did this new boom come about in Europe? Why is it that we run? Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary SyndromesPARIS - - SEPIA-ACS Multiple-Dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet - Neuromuscular Disease Treatment Catena(R) Available in Europe on a Named Patient BasisLIESTAL, Switzerland and WEYBRIDGE, England - - Santhera and Idis Partner to Facilitate Patient Access to Friedreich’s Ataxia Drug Partnership Between Celesio and Panfarma SealedVITORIA, Brazil - - Federal Minister of Economics Karl-Theodor zu Guttenberg: “Clear Signal for Growth” Health Robotics Expands CytoCare(TM) Global Presence With National Taiwan University Hospital and PinnaclemedBOZEN, Italy - Health Robotics today announced that National Taiwan University Hospital (NTUH) has purchased and agreed to immediately install its flagship CytoCare Robot during 2009. Separately, it also announced that it has signed an exclusive 3-year distribution, licensing, and support contract with Pinnaclemed [a Double Success Co. Ltd. subsidiary]. Both NTUH and Pinnaclemed desire to safely, accurately, and cost-effectively automate the preparation of hazardous Oncology I.V. Admixtures with Health Robotics’ CytoCare Robot in Taiwan. PerkinElmer Launches First-in-Class Test Kit to Measure Multiple Steroids Simultaneously for Diagnosis of Hormone and Endocrine DisordersBREMEN, Germany - - CHS(TM) Steroid Profiling Kit and Data Suite Software Delivers Faster and More Accurate Results for Endocrine Testing in Children and Adults Team Garmin-Slipstream Announces POM Wonderful SponsorshipLOS ANGELES - - Team Garmin-Slipstream athletes to be fueled by POM Wonderful 100% Pomegranate Juice in 2010 Eight out of 10 People Diagnosed With Heart Disease Consider Their Diagnosis a ‘Wake-Up Call’BARCELONA, Spain - - Your Heart: New Start initiative launched to provide heart patients and their carers with information about nutrition, fitness and medication adherence Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology CongressMONT-SAINT-GUIBERT, Belgium - - Symposium Session Draws Leading Experts to Review Recent Developments in Cardiac Regenerative Therapies Largest Registry to Date to Provide the First-Ever Picture of the Real Global Burden of Atrial Fibrillation (AF)BARCELONA, Spain - - Six-year GARFIELD Registry to prospectively follow 50,000 AF patients worldwide - New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing AngioplastyPARIS, and PRINCETON, New Jersey - -No added benefit on the composite primary end-point with the higher dose when entire ACS study population considered- Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary SyndromesPARIS - - SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet Data From Largest GOLD Stage II Patient Population Treated With Tiotropium Highlight the Benefits of Earlier Treatment of COPDINGELHEIM, Germany - - New UPLIFT(R) Analysis Shows Tiotropium Significantly Improves Lung Function and Quality of Life in COPD Patients With Early Stage Disease Omron Healthcare Reaches 100 Million Blood Pressure Monitor Units SoldKYOTO, Japan - Omron Healthcare Co., Ltd. announced on August 28 a new sales milestone for blood pressure monitors: 100 million units sold worldwide. The first Omron digital blood pressure monitor was launched in 1973 and since then, Omron Healthcare has introduced more than 100 models used in more than 100 countries around the world. Bavarian Nordic A/S - Half Year Interim Report 2009KVISTGAARD, Denmark - Today Bavarian Nordic published the company’s half-year interim report 2009. The full financial statements are available on the company’s website: www.bavarian-nordic.com. Below is an extract of the most significant matters in the report as well as events after the balance sheet date. Drugs Eclipse Alcohol in Child Custody TestsLONDON - There has been a significant increase in parents testing positive to drugs when required to undergo a hair test in child custody cases, according to the latest figures from Trimega Laboratories (www.trimegalabs.co.uk). Wyeth’s Torisel Approved by European Commission for the Treatment of Relapsed and/or Refractory Mantle Cell LymphomaMAIDENHEAD, England - Wyeth Europa Ltd., a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL). In the European Union (EU), TORISEL is also indicated for the first-line treatment of patients with advanced renal cell carcinoma who have at least three of six prognostic risk factors. Essilor : First Half 2009 ResultsPARIS - An Excellent First Half: - Contribution Margin Maintained at a High 18.2% - A Further Increase in Basic Earnings per Share - Sharp Rise in net Cash Flow Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A StrainsSARASOTA, Florida - Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies. Survey Reveals Diabetics Feel the Condition Impacts on Their Mood and Sex LifeLONDON - A new research study carried out by The Research Partnership reveals that living with diabetes can have a major effect on people’s lives, with just under half (44%) of type 2 patients reporting that the condition has impacted on either their ability or their desire to have sex. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment ToolsBOSTON, Massachusetts and CHEADLE, England - Cardea Technology, Inc. and Optasia Medical Ltd., announce plans to collaborate and configure their software tools for Vertebral Fracture Assessment, a method for evaluating vertebral fractures from images on bone densitometers, to exchange information and create reports for the management of osteoporosis. Spinal Implant Developed by Sanford Clinic Neurosurgeon Receives FDA 510(k) Market Clearance as a Lumbar Intervertebral Body Fusion DeviceSIOUX FALLS, South Dakota - Sanford Health (www.sanfordhealth.org), a comprehensive health care provider in the Upper Midwest, announced today a spinal implant developed by Sanford Clinic Neurosurgeon, Wilson Asfora, MD, Sanford Clinic Neurosurgery & Spine, has received United States Food and Drug Administration (FDA) 510(k) market clearance as a lumbar intervertebral body fusion device. On August 14, 2009, the FDA gave 510(k) clearance to the Asfora Bullet Cage, a product which is designed for use in posterior lumbar interbody fusion surgeries to treat degenerative disc disease. The Asfora Bullet Cage will be manufactured and sold by Medical Designs, LLC, a Sioux Falls company owned by Dr. Asfora. ThromboGenics NV Announces Business Update and Half Year Results 2009LEUVEN, Belgium - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009. |
